CRSP
Price
$40.53
Change
+$0.23 (+0.57%)
Updated
Jan 17 closing price
Capitalization
3.46B
31 days until earnings call
XERS
Price
$3.20
Change
-$0.02 (-0.62%)
Updated
Jan 17 closing price
Capitalization
477.06M
46 days until earnings call
Ad is loading...

CRSP vs XERS

Header iconCRSP vs XERS Comparison
Open Charts CRSP vs XERSBanner chart's image
CRISPR Therapeutics AG
Price$40.53
Change+$0.23 (+0.57%)
Volume$1.39M
Capitalization3.46B
Xeris Biopharma Holdings
Price$3.20
Change-$0.02 (-0.62%)
Volume$893.05K
Capitalization477.06M
CRSP vs XERS Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. XERS commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and XERS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CRSP: $40.53 vs. XERS: $3.20)
Brand notoriety: CRSP and XERS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 74% vs. XERS: 58%
Market capitalization -- CRSP: $3.46B vs. XERS: $477.06M
CRSP [@Biotechnology] is valued at $3.46B. XERS’s [@Biotechnology] market capitalization is $477.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileXERS’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • XERS’s FA Score: 0 green, 5 red.
According to our system of comparison, XERS is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 5 TA indicator(s) are bullish while XERS’s TA Score has 1 bullish TA indicator(s).

  • CRSP’s TA Score: 5 bullish, 2 bearish.
  • XERS’s TA Score: 1 bullish, 5 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than XERS.

Price Growth

CRSP (@Biotechnology) experienced а +2.12% price change this week, while XERS (@Biotechnology) price change was -5.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CRSP is expected to report earnings on May 12, 2025.

XERS is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($3.46B) has a higher market cap than XERS($477M). CRSP YTD gains are higher at: 2.973 vs. XERS (-5.605). XERS has higher annual earnings (EBITDA): -23.07M vs. CRSP (-313.08M). CRSP has more cash in the bank: 1.94B vs. XERS (69.4M). CRSP has less debt than XERS: CRSP (228M) vs XERS (271M). CRSP has higher revenues than XERS: CRSP (200M) vs XERS (187M).
CRSPXERSCRSP / XERS
Capitalization3.46B477M725%
EBITDA-313.08M-23.07M1,357%
Gain YTD2.973-5.605-53%
P/E RatioN/AN/A-
Revenue200M187M107%
Total Cash1.94B69.4M2,790%
Total Debt228M271M84%
FUNDAMENTALS RATINGS
CRSP vs XERS: Fundamental Ratings
CRSP
XERS
OUTLOOK RATING
1..100
6571
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
8545
P/E GROWTH RATING
1..100
82100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (63) in the Biotechnology industry is in the same range as XERS (93) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to XERS’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to XERS’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to XERS’s over the last 12 months.

XERS's Price Growth Rating (45) in the Pharmaceuticals Major industry is somewhat better than the same rating for CRSP (85) in the Biotechnology industry. This means that XERS’s stock grew somewhat faster than CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (82) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to XERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPXERS
RSI
ODDS (%)
Bullish Trend 11 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 11 days ago
77%
Bearish Trend 11 days ago
82%
Momentum
ODDS (%)
Bullish Trend 11 days ago
76%
Bearish Trend 11 days ago
85%
MACD
ODDS (%)
Bullish Trend 11 days ago
72%
Bearish Trend 11 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
78%
Bearish Trend 11 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
86%
Bearish Trend 11 days ago
86%
Advances
ODDS (%)
Bullish Trend 17 days ago
81%
Bullish Trend 16 days ago
84%
Declines
ODDS (%)
Bearish Trend 11 days ago
84%
Bearish Trend 12 days ago
83%
BollingerBands
ODDS (%)
N/A
Bearish Trend 11 days ago
90%
Aroon
ODDS (%)
Bearish Trend 11 days ago
84%
N/A
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LGLVX51.940.54
+1.05%
Lord Abbett Growth Leaders R6
FGJMX114.021.08
+0.96%
Fidelity Advisor Communication ServicesI
SEVIX14.190.04
+0.28%
SEI US Managed Volatility I (SIMT)
EFCAX21.61N/A
N/A
Emerald Insights A
MMSIX12.28N/A
N/A
Praxis Small Cap Index I

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+0.57%
BEAM - CRSP
71%
Closely correlated
+0.17%
PRME - CRSP
63%
Loosely correlated
+0.70%
RXRX - CRSP
63%
Loosely correlated
+2.03%
NTLA - CRSP
61%
Loosely correlated
+0.85%
EDIT - CRSP
59%
Loosely correlated
-1.61%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with TRDA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
-0.62%
TRDA - XERS
45%
Loosely correlated
+1.20%
SCPH - XERS
44%
Loosely correlated
-4.09%
FHTX - XERS
40%
Loosely correlated
+2.62%
CRSP - XERS
40%
Loosely correlated
+0.57%
IMNM - XERS
39%
Loosely correlated
+1.32%
More